G

GemPharmatech Co Ltd
SSE:688046

Watchlist Manager
GemPharmatech Co Ltd
SSE:688046
Watchlist
Price: 12.94 CNY -6.71% Market Closed
Market Cap: 5.3B CNY
Have any thoughts about
GemPharmatech Co Ltd?
Write Note

GemPharmatech Co Ltd
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

GemPharmatech Co Ltd
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
G
GemPharmatech Co Ltd
SSE:688046
Operating Income
ÂĄ155.4m
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Operating Income
ÂĄ10.6B
CAGR 3-Years
37%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Operating Income
ÂĄ1.6B
CAGR 3-Years
5%
CAGR 5-Years
25%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Operating Income
ÂĄ3.9B
CAGR 3-Years
10%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Operating Income
ÂĄ1.4B
CAGR 3-Years
6%
CAGR 5-Years
14%
CAGR 10-Years
27%
W
WuXi XDC Cayman Inc
HKEX:2268
Operating Income
ÂĄ410.8m
CAGR 3-Years
127%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

GemPharmatech Co Ltd
Glance View

Market Cap
5.3B CNY
Industry
Life Sciences Tools & Services

GemPharmatech Co., Ltd. engages in research and development, manufacture, and sale of experimental mouse models. The company is headquartered in Nanjing, Jiangsu and currently employs 1,342 full-time employees. The company went IPO on 2022-04-25. The firm uses gene-editing and other technologies to produce mouse models. The firm also involves in the business of customized model breeding, drug efficacy analysis, and model customization. The Company’s products are mainly used to satisfy the experimental demands in the fields of gene function cognition, disease mechanisms analysis, drug target discovery, and other fundamental researches.

Intrinsic Value
20.3 CNY
Undervaluation 36%
Intrinsic Value
Price
G

See Also

What is GemPharmatech Co Ltd's Operating Income?
Operating Income
155.4m CNY

Based on the financial report for Dec 31, 2023, GemPharmatech Co Ltd's Operating Income amounts to 155.4m CNY.

What is GemPharmatech Co Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
22%

Over the last year, the Operating Income growth was -4%. The average annual Operating Income growth rates for GemPharmatech Co Ltd have been 22% over the past three years .

Back to Top